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BACKGROUND: Previous analyses from a randomised trial in women aged 24–45 years have shown the quadrivalent human
papillomavirus (qHPV) vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN), and external
genital lesions (EGLs) related to HPV 6/11/16/18. In this report, we present end-of-study efficacy, safety, and immunogenicity data
with a median follow-up time of 4.0 years.
METHODS: We enrolled 3819 24–45-year-old women with no history of cervical disease or genital warts in the past 5 years. Women
received quadrivalent vaccine or placebo at day 1, and at months 2 and 6. Ascertainment of CIN/EGL was accomplished through Pap
testing, genital inspection, and cervicovaginal sampling (every 6 months). The main analysis was conducted in a per-protocol efficacy
population (that received three doses, was naive to the relevant HPV types at day 1, and remained free of infection through month 7).
Efficacy was also estimated in other naive and non-naive populations.
RESULTS: Vaccine efficacy against the combined incidence of persistent infection, CIN/EGL related to HPV6/11/16/18 in the per-
protocol population was 88.7% (95% CI: 78.1, 94.8). Efficacy for women who were seropositive and DNA negative for the relevant
vaccine HPV type at the time of enrolment who received at least 1 dose was 66.9% (95% CI: 4.3, 90.6). At month 48, 91.5, 92.0, 97.4,
and 47.9% of vaccinated women were seropositive to HPV 6/11/16/18, respectively. No serious vaccine-related adverse experiences
were reported.
CONCLUSIONS: The qHPV vaccine demonstrated high efficacy, immunogenicity, and acceptable safety in women aged 24–45 years,
regardless of previous exposure to HPV vaccine type.
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Persistent infection of the uterine cervix by 15–20 carcinogenic
human papillomavirus (HPV) genotypes leads to the vast majority
of cervical cancers (Walboomers et al, 1999; Mun ˜oz et al, 2003)
and related precursor lesions (International Agency for Research
on Cancer Working Group, 2007). Although most sexually active
women are at risk of HPV infection, the incidence of HPV
infection peaks soon after the onset of sexual activity in most
populations (Jacobs et al, 2000; Schiffman and Kjaer, 2003; Dunne
et al, 2007). Although incidence rates tend to decline thereafter,
women older than age 25 years also remain at risk for acquisition
of new HPV infections (Castellsague et al, 2009; Munoz et al, 2009).
Data from Colombia show that the 5-year cumulative risk of
incident cervical HPV infection decreased from 42.5% in females
aged 15–19 years to 30% in those aged 25–29 years, and to 22% in
those aged 30–44 years (Munoz et al, 2004). However, a second
peak in HPV DNA prevalence has been observed in women in the
fourth and fifth decades of life (de Sanjose et al, 2007). Whether
this second peak is due to new infections, viral reactivation,
waning immunity, or another mechanism is unclear. The cohort
study from Colombia supports the possibility of new infections, as
the curve of incident high-risk HPV infections is also bimodal with
a first peak in women under 25 years of age and a second peak
after menopause (Munoz et al, 2004). Conflicting evidence with
respect to a bimodal infection peak is provided byRodriguez et al
(2010), although these two studies are not directly comparable.
Previous studies have demonstrated that the prophylactic
quadrivalent HPV (qHPV) vaccine is highly effective in preventing
HPV 6-, 11-, 16-, or 18-related high-grade cervical, vulvar, or
vaginal intraepithelial neoplasia (CIN, VIN, or VaIN, respectively),
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sas well as adenocarcinoma in situ (AIS) in women aged 16–26
years, who are negative to the respective vaccine HPV types at the
time of enrolment (Garland et al, 2007; The FUTURE II Study
Group, 2007b). High efficacy against HPV 6- and 11-related genital
warts was also seen (Garland et al, 2007). Data from these trials
indicated that women who are negative to all four vaccine HPV
types (negative by both serological and DNA testing) before
vaccination derive full benefit (i.e., protection from disease caused
by all four vaccine HPV types). Women who have evidence of
infection with X1 vaccine HPV types before vaccination derive
only partial benefit (i.e., protection from the types which subjects
were not infected with at the time of vaccination) (The FUTURE II
Study Group, 2007a).
In addition, recently published interim data support the efficacy
of the qHPV vaccine in susceptible women aged 24–45 years.
Among per-protocol populations of women aged 24–45 years
(85.2% of all vaccinated subjects were included in the per-protocol
population), vaccine efficacy against the combined incidence of
persistent infection, cervical, and external genital disease related to
HPV 6, 11, 16, and 18 was 90.5% (95% CI: 73.7–97.5) (Munoz et al,
2009). Vaccine efficacy against the co-primary end point
(combined incidence of persistent infection of X6 months
duration, cervical, and external genital disease related to HPV 16
and 18) was 83.1% (95% CI: 50.6, 95.8) (Munoz et al, 2009). These
interim data were based on a mean follow-up time of 2.2 years. As
this trial is now complete, a reanalysis of all data gathered during
the trial is presented, inclusive of the data originally published by
Munoz et al.
In this report, we further evaluate the efficacy, safety, and
immunogenicity of the prophylactic qHPV vaccine in 24–45-year-
old women, using end-of-study data obtained from an interna-
tional randomised, placebo-controlled phase III clinical trial with a
median follow-up time of 4.0 years (mean of 3.8 years). These final
data help define the benefit women 24–45 years of age will get
from prophylactic HPV vaccination.
MATERIALS AND METHODS
Study design
Between 18 June 2004 and 30 April 2005, 3819 women between the
ages of 24 and 45 years were enrolled at 38 international study sites
into an ongoing randomised, placebo-controlled, double-blind
safety, immunogenicity, and efficacy study (Protocol 019;
NCT00090220). Subjects were enrolled from community health
centres, academic health centres, and primary health-care
providers in Colombia, France, Germany, Philippines, Spain,
Thailand, and the United States. The current report represents
the end-of-study analysis, after a median follow-up time of 4.0
years.
Women were eligible to participate in the study if they were not
pregnant and if they had not undergone hysterectomy. Subjects
were asked to use effective contraception through month 7 of the
study. Women with a history of genital warts or current/past
cervical disease (CIN or cancer) were not eligible for enrolment.
Those with previous cervical definitive therapy and those having
undergone a cervical biopsy within the past 5 years were also
excluded. In addition, those subjects infected with HIV (human
immunodeficiency virus) and those who were otherwise immuno-
compromised were not eligible for enrolment. Lifetime number of
sexual partners was not an inclusion or exclusion criterion.
The Institutional Review Board at each participating centre
approved the protocol, and informed consent was obtained from
all subjects. Studies were conducted in conformance with
applicable country or local requirements regarding ethics com-
mittee review, informed consent, and other statutes or regulations
regarding the protection of the rights and welfare of human
subjects participating in the biomedical research.
Vaccine
Subjects were stratified into two age strata (p34 and X35 years)
and randomised in an B1:1 ratio to receive either qHPV (types 6,
11, 16, 18) L1 VLP vaccine (GARDASIL/SILGARD, Merck & Co.
Inc., Whitehouse Station, NJ, USA) or visually indistinguishable
adjuvant-containing placebo at day 1, and at months 2 and 6.
Details of the qHPV vaccine have been published previously
(Olsson et al, 2007).
A computer-generated allocation schedule was generated by the
sponsor’s Clinical Biostatistics department. Following informed
consent and determination that all entry criteria were met,
eligible subjects were randomised to a vaccination group
using an Interactive Voice Response System. Recruitment was
designed to approximately achieve equal proportions between the
two age strata study-wide. All study-site investigators and
personnel, study participants, monitors, and central laboratory
personnel, remained blinded to treatment allocation throughout
the study.
Efficacy end points and case definition
The co-primary efficacy end points were (1) the combined
incidence of HPV 6-, 11-, 16-, or 18-related persistent infection
(X6 months duration), cervical, and external genital disease
(includes CIN, VIN, VaIN, AIS, cervical, vulvar, or vaginal cancer,
and genital warts) and (2) the combined incidence of HPV 16- or
18-related persistent infection, cervical, and external genital
disease. The secondary efficacy end point was the combined
incidence of HPV 6- or 11-related persistent infection, cervical,
and external genital disease. The first co-primary efficacy
hypothesis was to be tested with X25 cases of the first co-primary
efficacy end point and X14 cases of the second co-primary efficacy
end point were observed (i.e., fixed event design). The second
primary hypothesis was to be tested only if the first co-primary
hypothesis test was successful. The secondary hypothesis was to be
tested when X19 cases of the secondary efficacy end point were
observed, and only if both co-primary hypothesis tests were
successful. Under an assumed incidence of 0.6, 0.2, and 0.6 per 100
person-years (Mun ˜oz et al, 2006; Insinga et al, 2007), correspond-
ing to HPV 16-, HPV 18-, and HPV 6/11-related persistent
infection and disease, respectively, the study with 3819 subjects has
87 and 80% power to achieve success on the co-primary and
secondary hypotheses, respectively, if the vaccine is at least 80%
efficacious.
Persistent infection was defined as detection of the same HPV
type in cervicovaginal/anogenital swabs at X2 consecutive visits
spaced X6 months apart (±1 month visit window), or the
presence of cervical/genital disease associated with the relevant
type with type-specific HPV DNA detected in cervicovaginal or
anogenital swabs at the visit directly before or after biopsy. Disease
was defined as a tissue sample diagnosed by a four-member
pathology panel as CIN, AIS, VIN, VaIN, genital warts, or cervical,
vulvar, or vaginal cancer with type-specific HPV DNA detected in
tissue from the same lesion, as described previously (Garland et al,
2007).
Safety and immunogenicity objectives
The primary safety objective was to demonstrate that a three-
dose regimen of qHPV vaccine is generally well tolerated in women
aged 24–45 years. The primary immunogenicity objectives
included (1) evaluation of the kinetics and age dependence of
anti-HPV 6, 11, 16, and 18 responses after administration of a
three-dose regimen of qHPV vaccine and (2) comparison of anti-
HPV 6, 11, 16, and 18 responses after administration of a three-
dose regimen of qHPV vaccine among HPV-negative women aged
24–45 years.
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For ascertainment of disease, a complete gynaecological examina-
tion was performed at day 1 and at months 7, 12, 24, 36, and 48,
which included a pelvic exam (both speculum and bimanual
exams). External genital inspections were performed using a
magnifying glass at day 1 and at months 7, 12, 18, 24, 30, 36, 42,
and 48. Labial/vulvar/perineal, and perianal swabs, as well as endo/
ecto cervical swabs for HPV Multiplex PCR testing were obtained
at day 1 and at months 7, 12, 18, 24, 30, 36, 42, and 48. ThinPrep
(Cytyc, Boxborough, MA, USA) Pap tests were also collected
during these visits. Once received, cytology specimens were
evaluated using the Bethesda System-2001 (Solomon et al, 2002).
Referral for colposcopy was algorithm based. Histological speci-
mens were first interpreted for clinical management by patholo-
gists at a central laboratory (Diagnostic Cytology Laboratories,
Indianapolis, IN, USA), and then evaluated for end point
determination by a blinded panel of four pathologists. If indicated,
definitive therapy was performed.
Serum for immunogenicity testing was collected before vaccina-
tion on day 1, and at months 7, 12, 24, 36, and 48. Antibody
responses and the proportion of subjects seroconverting for
vaccine-type epitope-specific neutralising anti-HPV antibodies
were analysed using a competitive Luminex-based immunoassay
(cLIA) developed by Merck Research Laboratories as described
previously (Opalka et al, 2003).
Adverse experiences were solicited from subjects by general
questioning at study visits and using a vaccine report card (VRC).
The VRC was provided to the subject at each vaccination visit to
record temperatures, as well as local and systemic adverse
experiences.
Statistical analysis
No tests of hypothesis were conducted in the current analyses.
The final tests relating to the study co-primary and secondary
efficacy hypotheses were conducted previously, the results of
which were published in the study by Munoz et al (2009). The
results presented in this report are the updated estimates of
efficacy of the qHPV vaccine against the co-primary and secondary
efficacy end points and against selected exploratory efficacy
end points.
Populations studied
Efficacy analysis was conducted in the per-protocol efficacy (PPE)
population, that is, subjects who were seronegative at day 1 and
PCR-negative (swab and biopsy specimens) from day 1 through
month 7 to the relevant vaccine HPV type(s) and did not violate
the protocol. The PPE-eligible participants received all 3 vaccina-
tions within 1 year, and had 1 or more follow-up visits after month 7.
Case counting commenced at month 7.
Analyses were also conducted in an intention-to-treat (ITT)
population consisting of subjects who received X1 dose of vaccine
or placebo and returned for follow-up. These subjects could have
been seropositive and/or PCR positive to vaccine HPV types at
enrolment, and represent a general non-vaccinated population. In
addition, this population also includes subjects who were baseline
positive to non-vaccine HPV types. Case counting in the ITT
population commenced after day 1.
Additional analyses were conducted in a population of subjects
deemed ‘naive to the relevant HPV type’ (NRT). This population
consisted of subjects who received X1 dose of vaccine or placebo,
returned for follow-up, and were DNA negative at enrolment for
the HPV type of interest. In addition, these subjects were
seronegative at enrolment for the HPV type of interest, if it was
one of the four vaccine HPV types. The NRT case counting began
after day 1.
Role of the funding source
The studies were designed by the sponsor (Merck & Co. Inc.) in
collaboration with external investigators and an external data and
safety monitoring board. The sponsor collated data, monitored the
conduct of the study, performed statistical analysis, and coordi-
nated the writing of the manuscript with all authors. The authors
were actively involved in the collection, analysis, or interpretation
of data, the revising of the manuscript for intellectual content, and
approved the final manuscript. All authors had access to data and
participated in the decision on where to submit the paper for
publication.
RESULTS
Overall, 3819 women (mean age 34.3±6.3 years) were enrolled into
the study and randomised to receive either qHPV vaccine or
placebo. A total of 3692 women (96.7%) received all three
vaccinations and entered the follow-up period. Key baseline
characteristics were generally similar between subjects in the
vaccine and placebo groups (Table 1). Almost all women were non-
virgins at enrolment (99.9%); and the mean age of sexual debut
was 19 (±3.7) years. Detailed information on enrolment, baseline
characteristics, and sexual history of the study population can be
seen in the study by Munoz et al (2009).
Table 1 Baseline characteristics and HPV DNA status of enrolled
subjects
Vaccine
(N¼1911) n (%)
Placebo
(N¼1908) n (%)
Age (years)
Mean±s.d. 34.3±6.3 34.3±6.3
Median 35 34
Range 24–45 21–46
Lifetime no. of sexual partners
1 713 (37.6) 751 (39.4)
2 385 (20.2) 362 (19.0)
3 229 (12.0) 223 (11.7)
4 142 (7.4) 130 (6.8)
44 433 (22.7) 437 (22.9)
Median 2 2
Contraceptive use
Barrier 441 (23.1) 425 (22.3)
Behaviour 165 (8.6) 184 (9.6)
Hormonal 596 (31.2) 591 (31.0)
Other
a 748 (39.2) 749 (39.3)
Baseline HPV DNA prevalence
All vaccine types 159 (8.4) 139 (7.4)
HPV 6 34 (1.8) 37 (1.9)
HPV 11 4 (0.2) 5 (0.3)
HPV 16 93 (4.9) 77 (4.0)
HPV 18 39 (2.0) 40 (2.1)
All tested non-vaccine types 406 (21.6) 380 (20.3)
HPV 31 52 (2.7) 52 (2.7)
HPV 33 17 (0.9) 10 (0.5)
HPV 35 23 (1.2) 26 (1.4)
HPV 39 60 (3.1) 52 (2.7)
HPV 45 33 (1.7) 32 (1.7)
HPV 51 79 (4.1) 61 (3.2)
HPV 52 81 (4.2) 90 (4.7)
HPV 56 119 (6.2) 119 (6.3)
HPV 58 59 (3.1) 41 (2.2)
HPV 59 34 (1.8) 50 (2.6)
Abbreviations: N¼number of subjects enrolled; n¼number of subjects in each
category; HPV¼human papillomavirus.
aOther includes female or male sterilisation
and intrauterine devices.
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18 at baseline by serology or DNA testing, but most of these
women (91%) were positive to none or only 1 of the 4 vaccine
types. Geometric mean antibody titres in response to qHPV
vaccine peaked at month 7 and declined to relative stability
between months 24 and 48 (Figure 1). A vast majority of previously
HPV-negative vaccinated women seroconverted for HPV 6
(98.4%), 11 (98.1%), 16 (98.8%), and 18 (97.3%) by month 7. At
month 48, 91.5, 92.0, 97.4, and 47.9% of vaccinated women were
still considered seropositive to HPV 6, 11, 16, and 18, respectively
(as defined by the cLIA assay). Antibody titres for the placebo
group were within the margin of error for the assay and were not
plotted. In general, women seropositive to a particular vaccine
HPV type at enrolment (who were subsequently vaccinated) had
higher antibody titres for that type throughout follow-up than did
women who were negative to that type at enrolment (Supplemen-
tary Figure 1). As compared with seronegative women, month 48
geometric mean titre levels were greater in women seropositive
and DNA negative for HPV 6, 11, 16, and 18 at enrolment by 7.8-,
13.2-, 4.2-, and 15.1-fold, respectively.
In the PPE population, an additional 53 cases related to vaccine
HPV types were observed (7 vaccine and 46 placebo) subsequent to
the original analyses of data previously published (Table 2)
(Munoz et al, 2009). All seven additional cases observed in the
vaccine group were cases of persistent infection. The one case of
CIN 2/3 in the vaccine group at the end of study was observed in
the original study follow-up. The HPV DNA types detected among
subjects with cases of HPV 6/11/16/18-related persistent infection,
CIN, or external genital lesions EGL in the PPE population vaccine
group can be seen in Supplementary Table 1. In the NRT and ITT
populations (ITT), 60 and 68 additional cases of infection and/or
disease related to vaccine HPV types were observed, respectively.
In the PPE population, there were 10 cases of infection and/or
disease related to vaccine HPV types in the vaccine group as shown
in Table 2. Three cases were observed during the 2007 end point-
driven analysis and seven in the additional follow-up period.
Only 1 of the 10 cases had HPV 16-persistent infection alone. The
HPV 6, 11, 16, and 18 antibody titres at month 7 for this potential
breakthrough case were 2513, 3775, 7850, and 1532 (uMUml
 1),
respectively. Six other cases had persistent infections with both
HPV 16 and other high-risk non-vaccine types, one case had HPV
16- and 18-persistent infections with other high-risk non-vaccine
types, and two cases had HPV 6-persistent infection with other
high-risk non-vaccine types.
Vaccine efficacy against the combined incidence of persistent
infection, CIN, or EGL related to vaccine HPV types in the PPE,
NRT, and ITT populations was 88.7% (95% CI: 78.1, 94.8), 79.9%
(95% CI: 69.4, 87.3), and 47.2% (95% CI: 33.5, 58.2), respectively
(Table 2). Efficacy against the combined incidence of persistent
infection, CIN, or EGL in the PPE population related to vaccine
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Figure 1 Summary of the persistence of anti-HPV geometric mean titres (GMTs) in women receiving the qHPV vaccine (also see Supplementary Figure 1
stratified by baseline vaccine-type serostatus). The dots shown the in plot correspond to estimates of GMTs. The vertical bars superimposed to each dot
represent the 95% confidence interval associated with the estimated GMT. The mini-vertical axes immediately to the left of the vertical bars show the range
of the 95% confidence interval specific to each GMT estimate. The length of each vertical bar is relative only to the mini-scale immediately to the left of the
vertical bar. The length of the vertical bars across time points is not comparable. Comparisons of statistically significant difference or absence of statistically
significant difference between GMTs over time should not be made on the basis of comparisons of the length of the vertical bars. The antibody titres for the
placebo group were within the margin of error for the assay and were not plotted.
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years and 83.8% (95% CI: 57.9, 95.1) in women aged 35–45 years
(data not shown). Efficacy against any grade CIN related to vaccine
HPV types was statistically significant for all three analysis
populations; however, efficacy estimates for CIN 2/3 or worse in
the PPE, NRT, and ITT analysis populations did not reach
statistical significance. Vaccine efficacy against the combined
incidence of persistent infection, CIN, or EGL in the PPE and ITT
populations related to HPV 16/18 was 84.7% (95% CI: 67.5, 93.7)
and 41.6% (95% CI: 24.3–55.2), respectively (Table 2). Vaccine
efficacy against the combined incidence of persistent infection,
CIN, or EGL in the PPE and ITT populations related to HPV 6/11
was 94.8% (95% CI: 79.9, 99.4) and 61.3% (95% CI: 38.8, 76.2),
respectively (data not shown). Prevalent HPV 6/11/16/18 infection,
which is present at baseline, was largely responsible for the lower
estimate of efficacy in the ITT population against the composite
end point. Supplementary Figure 2 illustrates the marked
differences in incidence by baseline infection status. Overall
efficacy estimates were somewhat lower in the older age group
(35–45 years), but differences were not statistically significant.
Efficacy estimates for HPV infection of at least 6- and 12-month
duration were comparable.
In the ITT analysis of high-grade CIN regardless of HPV
type, there was an imbalance of baseline infection and disease
at randomisation that resulted in a higher number of cases
of CIN 2/3 or worse in the vaccine group as compared with the
placebo group. As shown in Table 3, this excess number of CIN 2/3
cases was mainly due to non-vaccine HPV types. Table 1 shows
that HPV types 33, 39, 51, and 58 accounted for a substantial
imbalance of proportion of the cases of infection at baseline.
The high level of background HPV infection due to these 4 HPV
types accounted for 20 cases of CIN 2/3 or worse in the vaccine
group vs 5 cases in the placebo group. Of the 20 cases of CIN 2/3 or
worse, 11 were diagnosed within the first 4 months of the study
(Table 4).
Vaccine efficacy in reducing the incidence of any abnormal Pap
smear related to any vaccine HPV types during follow-up was
97.4% (95% CI: 84.5, 99.9) in the PPE population and 50.1% (95%
CI: 24.2, 67.8) in the ITT population (Table 5). Efficacy point
estimates in the PPE population did not differ substantially by age
group, HPV type, or severity of Pap abnormality. Efficacy against
the incidence of abnormal Pap smears related to HPV 16 or 18 was
96.3% (95% CI: 77.7, 99.9) in the PPE population and 47.5% (95%
CI: 16.9, 67.4) in the ITT population (data not shown).
Table 2 End-of-study efficacy against the combined incidence of vaccine type-related infection of 6 months duration, CIN or EGL
HPV 6/11/16/18-related outcomes HPV 16/18-related outcomes
n(m)
Observed
n(m)
Observed
Analysis population end point qHPV Placebo efficacy 95% CI qHPV Placebo efficacy 95% CI
Per-protocol efficacy population (PPE)
Overall persistent infection, CIN, or EGL 10 (4) 86 (41) 88.7 (78.1, 94.8) 8 (4) 51 (23) 84.7 (67.5, 93.7)
24–34-year-olds 5 (2) 56 (24) 91.3 (78.4, 97.3) 5 (2) 35 (13) 86.0 (64.0, 95.7)
35–45-year-olds 5 (2) 30 (17) 83.8 (57.9, 95.1) 3 (2) 16 (10) 81.8 (36.3, 96.6)
By end point
Persistent infection 9 (2) 85 (39) 89.6 (79.3, 95.4) 7 (2) 50 (21) 86.2 (69.4, 94.7)
CIN (any grade) 1 (1) 17 (9) 94.1 (62.5, 99.9) 1 (1) 13 (7) 92.4 (49.1, 99.8)
CIN 2/3 or worse 1 (1) 6 (4) 83.3 ( 37.6, 99.6) 1 (1) 6 (4) 83.4 ( 36.7, 99.6)
EGL 0 (0) 7 (4) 100 (30.8, 100) 0 (0) 0 (0) NA NA
Condyloma 0 (0) 7 (4) 100 (30.8, 100) 0 (0) 0 (0) NA NA
VIN 2/3 or VaIN 2/3 0 (0) 0 (0) NA NA 0 (0) 0 (0) NA NA
HPV-naive to the relevant type population (NRT)
Overall persistent infection, CIN, or EGL 27 (20) 130 (77) 79.9 (69.4, 87.3) 19 (14) 85 (48) 78.3 (64.0, 87.5)
24–34-year-olds 15 (11) 90 (54) 83.7 (71.7, 91.3) 13 (9) 60 (33) 78.7 (60.7, 89.2)
35–45-year-olds 12 (9) 40 (23) 71.3 (44.1, 86.3) 6 (5) 25 (15) 78.0 (42.6, 92.3)
By end point
Persistent infection 26 (19) 129 (76) 80.4 (69.9, 87.7) 18 (13) 84 (47) 79.1 (64.9, 88.2)
CIN (any grade) 3 (3) 27 (16) 89.0 (64.1, 97.9) 3 (3) 21 (12) 85.9 (52.7, 97.3)
CIN 2/3 or worse 3 (3) 8 (4) 62.7 ( 55.5, 93.6) 3 (3) 8 (4) 62.9 ( 54.6, 93.7)
EGL 2 (1) 11 (8) 81.9 (17.2, 98.1) 1 (1) 0 (0) NA NA
Condyloma 1 (0) 11 (8) 91.0 (37.9, 99.8) 0 (0) 0 (0) NA NA
VIN 2/3 or VaIN 2/3 0 (0) 0 (0) NA NA 0 (0) 0 (0) NA NA
Intention-to-treat population (ITT)
Overall persistent infection, CIN, or EGL 116 (108) 214 (154) 47.2 (33.5, 58.2) 95 (90) 160 (115) 41.6 (24.3, 55.2)
24–34-year-olds 75 (71) 134 (94) 44.1 (25.3, 58.5) 60 (57) 100 (70) 39.4 (16.0, 56.9)
35–45-year-olds 41 (37) 80 (60) 51.2 (28.0, 67.3) 35 (33) 60 (45) 43.9 (13.4, 64.1)
By end point
Persistent infection 110 (102) 211 (151) 49.0 (35.5, 59.9) 91 (86) 157 (112) 42.8 (25.5, 56.3)
CIN (any grade) 29 (25) 55 (41) 47.5 (16.3, 67.7) 28 (24) 48 (36) 41.9 (5.6, 64.9)
CIN 2/3 or worse 21 (19) 27 (21) 22.4 ( 42.5, 58.3) 21 (19) 27 (21) 22.4 ( 42.5, 58.3)
EGL 11 (9) 12 (9) 8.5 ( 126.6, 63.4) 3 (2) 0 (0) NA NA
Condyloma 7 (6) 12 (9) 41.8 ( 60.3, 80.6) 0 (0) 0 (0) NA NA
VIN 2/3 or VaIN 2/3 2 (1) 0 (0) NA NA 2 (1) 0 (0) NA NA
Abbreviations: CI¼confidence interval; CIN¼cervical intraepithelial neoplasia; EGL¼external genital lesion; NA¼not applicable; qHPV¼quadrivalent human papillomavirus
(types 6, 11, 16, 18) recombinant vaccine; VaIN; ¼vaginal intraepithelial neoplasia; VIN¼vulvar intraepithelial neoplasia. n¼number of cases at the end of study (mean follow-
up time per subject of 3.8 years); m¼number of cases in original report (mean follow-up time per subject of 2.2 years). Subjects are counted once in each applicable end point
category. A subject may appear in more than one category.
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12.6, 16.3, and 30.9% reduction seen in the occurrence of
colposcopy, biopsy, and any definitive therapy, respectively
(Supplementary Table 2). None of these reductions were
statistically significant.
Vaccine efficacy estimates against HPV6/11/16/18-related per-
sistent infection (there were no cases of CIN) in women with
serological evidence of previous HPV infection, but without
evidence of current infection (seropositive/DNA negative)
were calculated (Table 6). Overall efficacy in these women was
66.9% (95% CI: 4.3, 90.6). Women aged 35–45 years showed
higher efficacy than did women aged 24–34 years (81.3 vs 27.4%,
respectively); however this difference was not statistically
significant.
Vaccine safety and tolerability data are summarised in Table 7.
There was a slightly higher occurrence of overall adverse
experiences and vaccine-related adverse experiences in the
vaccinated group. This is largely due to the higher incidence of
overall and vaccine-related injection-site adverse experiences,
which were reported. No serious vaccine-related adverse experi-
ences were reported in either the vaccine or the placebo cohorts.
Reasons for discontinuation due to a vaccine-related adverse
experience in the vaccine group included hypersensitivity,
urticaria, mouth ulceration, injection-site swelling, and facial
oedema. Reasons for discontinuation due to a vaccine-related
adverse experience in the placebo group included fatigue and
overdose. Reasons for death in the vaccine group (n¼7) included
two cardiac arrests (one secondary to breast cancer metastasis and
the other secondary to cerebrovascular accident), acute liver
disease secondary to nasopharyngeal cancer, breast cancer,
tuberculosis, pulmonary embolism, and pericarditis. Death in the
placebo group resulted from pulmonary embolism.
DISCUSSION
Data from this clinical trial firmly confirm that the qHPV vaccine
is highly efficacious at preventing lower genital tract disease in
women up to age 45 years as based on the final 4-year data.
Efficacy estimates against the combined incidence of persistent
infection, CIN, or EGL related to vaccine HPV types in the PPE and
NRT populations were 88.7% (95% CI: 78.1, 94.8) and 79.9% (95%
CI: 69.4, 87.3), respectively. Although the observed efficacy of most
end points was largely comparable with previous evaluations in
this population (Munoz et al, 2009), there were exceptions,
particularly for the HPV 16- and 18-related end points in the
ITT population (Table 2). These newly significant efficacy results
are likely the result of additional follow-up and end point accrual.
The extra end points accrued during the 1.6 additional years of
follow-up increased precision of the efficacy estimates when
compared with those previously reported (Munoz et al, 2009).
These data reaffirm previous conclusions that prophylactic
administration of qHPV vaccine to 24- to 45-year-old women is
highly efficacious in preventing HPV 6-, 11-, 16-, and 18-related
infection and disease (genital warts, AIS, any grade CIN, VIN2/3,
VaIN 2/3).
Consistent with trial data from younger women, this end-of-
study analysis among women aged 24–45 years confirms that the
Table 4 Baseline imbalance of specific non-vaccine types (HPV types 33, 39, 51, and 58) and time of onset of CIN 2/3 cases occurring in the vaccine
group
Day 1 Month 1 Month 2 Month 3 Month 4
Case 1 HSIL; 33;52;58 33(CIN 3)
Case 2 LSIL; 33;58;59 33(CIN 2);58(CIN 2); 59(CIN 2);59(CIN 1);
33(CIN 3);58(CIN 3);59(CIN 3)
Case 3 HSIL; 16;35;58 51(CIN 3);58(CIN 3)
Case 4 51 51(CIN 2)
Case 5 HSIL; 16;58 16(CIN 1);58(CIN 1) 16(CIN 3);58(CIN 3);
16(CIN);58(CIN 1)
Case 6 ASCUS HR-HPV+; 31;58 31(CIN 2);58(CIN 2)
Case 7 LSIL; 51 51(CIN 2)
Case 8 HSIL; 16;39;52 — 39(CIN 3);16(CIN 1);39(CIN 1);
52(CIN 1)
Case 9 ASCUS HR-HPV+; 51 51(CIN 2)
Case 10 33 33(CIN 2)
Case 11 LSIL; 45;51;52 52(CIN 3); 52(CIN 2) 45(CIN 3);51(CIN 3);
52(CIN 3); 52(CIN 2)
Abbreviations: ASCUS¼Atypical squamous cells of undetermined significance; CIN¼cervical intraepithelial neoplasia; HSIL¼high-grade squamous intraepithelial lesion;
HPV¼human papillomavirus; HR¼high-risk probe result; LSIL¼low-grade squamous intraepithelial lesion.
Table 3 Cases of CIN 2/3 or worse due to vaccine and non-vaccine HPV types by baseline infection status in the ITT population
qHPV vaccine Placebo
Causal HPV type in CIN 2/3 Baseline HPV status Cases Rate Cases Rate
Any type Any 62 0.9 51 0.7
Vaccine type(s)
a 21 0.3 27 0.4
Day 1-negative for causal type 3 o0.1 8 0.1
Day 1-positive for causal type 18 3.9 19 4.7
Non-vaccine type(s)
b 40 0.6 25 0.4
Day 1-negative for causal type 13 0.2 4 0.1
Day 1-positive for causal type 30 2.3 22 1.8
Unknown type Any 9 0.1 9 0.1
Abbreviations: CIN¼cervical intraepithelial neoplasia; qHPV¼quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; ITT¼intention to treat. The sum of
the vaccine type-, non-vaccine type-, and unknown type-related cases is not equal to the any type-related cases as some subjects can have both vaccine type- and non-vaccine
type-related CIN 2/3 or worse.
aVaccine type(s)¼6, 11, 16, or 18.
bNon-vaccine type(s)¼31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.
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previous exposure to HPV 6/11/16/18 infection but with no
evidence of current infection (seropositive and DNA negative).
Efficacy against the combined end points was 66.9% overall and
reached 81.3% in the older age group (35–45 years). These data
suggest that women who had had previous infections or previous
exposure to HPV may benefit from vaccination with the qHPV
vaccine.
Vaccination with qHPV vaccine produced robust antibody
responses in women 24–45 years of age. Seropositivity to each of
the 4 vaccine HPV types exceeded 97% at 4 weeks after dose 3
(Munoz et al, 2009). At month 48, 91.5, 92.0, 97.4, and 47.9% of
women were still seropositive for HPV 6, HPV 11, HPV 16, and
HPV 18, respectively. Although these data indicate that HPV 18
seropositivity declined more quickly than did other vaccine HPV
types, no cases of infection or disease related to HPV 18 were seen
among vaccinees in the PPE population, similar to previous results
seen in younger women (Joura et al, 2008).
Administration of the qHPV vaccine was generally well
tolerated. The proportion of subjects who reported serious adverse
experiences was comparable between the qHPV vaccine group and
the placebo group. Few subjects discontinued study participation
because of an adverse experience. Although there was a slightly
higher incidence of adverse experiences in the vaccine group, these
results are largely due to increases in injection-site reactions, as
seen in other studies of the qHPV vaccine in women (Garland et al,
2007; The FUTURE II Study Group, 2007b; Munoz et al, 2009).
Although there were no serious vaccine-related adverse experi-
ences, there was an imbalance in the number of women
discontinuing because of adverse experiences, likely due to
increased injection-site adverse experiences. Moreover, consider-
ing the entire study follow-up, there were more women who died in
the vaccine group (n¼7) than in the placebo group (n¼1).
However, the reasons for death in these subjects were varied and
without a noticeable trend (Table 7). No study deaths were deemed
by investigators as related to vaccination.
The current study has several limitations. First, certain
restrictions to study entry may indicate that women in our study
were at somewhat lower risk of acquiring HPV than were women
in the general population (disease history, etc.). However, the
Table 5 Vaccine impact on the incidence of HPV 6/11/16/18-related Pap diagnoses
qHPV vaccine
(N¼1910)
Placebo
(N¼1907)
End point N Cases PYR Rate n Cases PYR Rate Efficacy (%) 95% CI
Per-protocol population
HPV 6/11/16/18-related ASC-US HR-HPV positive, or worse 1578 1 5028.7 0.0 1583 38 5006.5 0.8 97.4 (84.5, 99.9)
24–34-year-olds 771 1 2397.2 0.0 785 25 2442.5 1.0 95.9 (75.1, 99.9)
35–45-year-olds 807 0 2631.5 0.0 798 13 2564.0 0.5 100 (68.0, 100)
By HPV type
HPV 6 related 1299 0 4142.1 0.0 1304 12 4158.5 0.3 100 (63.9, 100)
HPV 11 related 1299 0 4142.1 0.0 1304 4 4169.3 0.1 100 ( 52.5, 100)
HPV 16 related 1322 1 4273.9 0.0 1312 21 4211.8 0.5 95.3 (70.8, 99.9)
HPV 18 related 1487 0 4740.9 0.0 1490 6 4750.7 0.1 100 (14.9, 100)
By severity
ASC-US HR-HPV positive 1578 1 5028.7 0.0 1583 13 5028.3 0.3 92.3 (48.8, 99.8)
LSIL or worse 1578 0 5030.6 0.0 1583 27 5021.7 0.5 100 (85.4, 100)
LSIL 1578 0 5030.6 0.0 1583 25 5023.4 0.5 100 (84.1, 100)
ASC-H 1578 0 5030.6 0.0 1583 1 5044.7 0.0 100 ( 3810.9, 100)
HSIL 1578 0 5030.6 0.0 1583 0 5045.5 0.0 NA NA
AGC 1578 0 5030.6 0.0 1583 1 5044.7 0.0 100 ( 3811.0, 100)
Adenocarcinoma 1578 0 5030.6 0.0 1583 0 5045.5 0.0 NA NA
Squamous cell carcinoma 1578 0 5030.6 0.0 1583 0 5045.5 0.0 NA NA
Intention-to-treat population
HPV 6/11/16/18-related ASC-US HR-HPV positive, or worse 1815 35 6675.9 0.5 1824 70 6656.4 1.1 50.1 (24.2, 67.8)
24–34-year-olds 884 23 3169.6 0.7 911 50 3268.9 1.5 52.6 (20.8, 72.4)
35–45-year-olds 931 12 3506.2 0.3 913 20 3387.5 0.6 42.0 ( 24.5, 74.2)
By HPV type
HPV 6 related 1833 6 6765.2 0.1 1835 14 6750.6 0.2 57.2 ( 18.5, 86.5)
HPV 11 related 1833 1 6769.6 0.0 1836 4 6763.4 0.1 75.0 ( 152.4, 99.5)
HPV 16 related 1822 25 6712.8 0.4 1825 46 6687.8 0.7 45.9 (10.0, 68.1)
HPV 18 related 1829 7 6747.6 0.1 1836 13 6746.5 0.2 46.2 ( 45.2, 81.8)
By severity
ASC-US HR-HPV positive 1829 17 6738.9 0.3 1835 33 6717.2 0.5 48.7 (5.1, 73.2)
LSIL or worse 1820 31 6696.4 0.5 1825 47 6695.2 0.7 34.1 ( 6.0, 59.5)
LSIL 1823 23 6708.7 0.3 1827 40 6702.2 0.6 42.6 (1.7, 67.2)
ASC-H 1832 5 6766.6 0.1 1835 2 6761.3 0.0  149.8 ( 2523.3, 59.1)
HSIL 1834 7 6770.4 0.1 1835 4 6764.6 0.1  74.9 ( 714.5, 55.5)
AGC 1833 0 6770.5 0.0 1836 1 6765.8 0.0 100 ( 3797.3, 100)
Adenocarcinoma 1834 0 6774.5 0.0 1836 1 6766.2 0.0 100 ( 3795.2, 100)
Squamous cell carcinoma 1834 0 6774.5 0.0 1836 0 6766.2 0.0 NA NA
Abbreviations: AGC¼atypical glandular cells; AIS¼adenocarcinoma in situ; ASC-H¼atypical squamous cells, cannot exclude HSIL; ASCUS¼atypical squamous cells of
undetermined significance; CI¼confidence interval; qHPV¼quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; HR¼high-risk probe result;
HSIL¼high-grade squamous intraepithelial lesion; LSIL¼low-grade squamous intraepithelial lesion; NA¼not applicable; Pap¼papanicolaou; SIL¼squamous intraepithelial
lesion; PYR¼person-years at risk; rate¼incidence rate per 100 PYR. Subjects are counted once in each applicable end point category. A subject may appear in more than one
category. N¼Number of subjects randomised to the respective vaccination group who received at least one injection. n¼Number of subjects who have at least one follow-up
visit after day 1.
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placebo group were similar of those reported in the literature
among women of similar age (data not shown) (Clifford et al,
2005). Second, because only 50–70% of HPV infections result in
detectable anti-HPV responses, the baseline serology test may have
underestimated previous exposure to HPV 6/11/16/18 in the study
population. Third, the lack of baseline serology measurements with
respect to non-vaccine HPV types affected our ability to define the
HPV-negative population with respect to non-vaccine HPV types.
This may have affected our CIN 2/3 efficacy results in the ‘HPV-
naive population’ with respect to non-vaccine HPV types. Finally,
this study was not powered to demonstrate statistically significant
efficacy for high-grade disease end points, and randomisation was
not designed to achieve treatment group balance with respect to
baseline prevalent infections on a by-HPV type basis. Thus, the
study was not able to demonstrate statistically significant efficacy
against CIN 2/3 in women aged 24–45 years. The treatment group
imbalance with respect to baseline prevalent infections further
negatively impacted the study’s ability to demonstrate positive
vaccine efficacy on high-grade CIN regardless of HPV type, as well
as on cervical and external genital procedures.
The implications of these findings are relevant to the construc-
tion of accurate recommendations on cervical cancer-preventative
strategies in adult women. On the basis of the reported efficacy
estimates of the qHPV vaccine and other trial data, mathematical
modellers are now provided with new data to perform more
precise cost-benefit and cost-effectiveness analyses assessing
various single and combined strategies for cervical cancer
prevention in adult women. It is clear that HPV vaccination is
likely to be beneficial to sexually active adult women as they are at
a continuous risk of acquiring new HPV infections and of
developing abnormal Pap smears, CIN, and cervical cancer
(Castellsague et al, 2009). However, public health recommenda-
tions for mass vaccination must take into consideration the cost-
effectiveness of vaccination programmes. Current vaccine and
implementation cost modelling studies have shown that vaccina-
tion becomes less cost-effective with the increasing age of the
target vaccination group. This is the main reason why the key
priority of all public health recommendations concerning HPV
vaccination is to target girls and young women for routine
vaccination, with or without catch-up programmes up to ages 25
or 26 years. As the overall cost benefit becomes progressively less
favourable with increasing age, most health authorities have not
widely recommended routine vaccination of older women. Never-
theless, as documented in this trial, sexually active women over the
age of 26 years also have the potential to benefit from vaccination
and should be allowed the opportunity to choose to be vaccinated
on an individual basis.
Table 6 Efficacy against HPV6/11/16/18-related persistent infection and disease in seropositive and PCR-negative subjects
qHPV vaccine (N¼1910) Placebo (N¼1907)
Observed
End point N Cases PYR Rate N Cases PYR Rate efficacy (%) 95% CI
HPV 6/11/16/18-related persistent infection, CIN, or EGL 506 5 1882.3 0.3 513 15 1868.0 0.8 66.9 (4.3, 90.6)
Persistent infection 496 5 1793.9 0.3 505 15 1788.7 0.8 66.8 (3.8, 90.5)
CIN (any grade) or EGL 506 0 1895.4 0.0 513 0 1901.2 0.0 NA NA
By HPV type and age group
HPV 6/11/16/18-related persistent infection (all ages) 496 5 1793.9 0.3 505 15 1788.7 0.8 66.8 (3.8, 90.5)
24–year-olds 258 3 909.9 0.3 248 4 880.6 0.5 27.4 ( 329.0, 89.4)
35–45 year-olds 238 2 884.0 0.2 257 11 908.2 1.2 81.3 (14.4, 98.0)
HPV 6/11-related persistent infection (all ages) 307 2 1128.2 0.2 297 4 1066.0 0.4 52.8 ( 229.7, 95.7)
24–34 year-olds 154 1 550.6 0.2 143 1 520.9 0.2 5.4 ( 7325.9, 98.8)
35–45 year-olds 153 1 577.6 0.2 154 3 545.2 0.6 68.5 ( 291.8, 99.4)
HPV 16/18-related persistent infection (all ages) 284 3 1020.9 0.3 312 11 1112.9 1.0 70.3 ( 12.5, 94.7)
24–34 year-olds 145 2 509.8 0.4 154 3 550.2 0.5 28.1 ( 528.1, 94.0)
35–45 year-olds 139 1 511.1 0.2 158 8 562.8 1.4 86.2 ( 2.7, 99.7)
Abbreviations: CI¼confidence interval; CIN¼cervical intraepithelial neoplasia; EGL¼external genital lesion; NA¼not applicable; PYR¼person years at risk;
qHPV¼quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; rate¼incidence rate per 100 person years at risk. N¼Number of subjects randomised
to the respective vaccination group who received at least 1 injection and were seropositive and DNA negative for the relevant vaccine HPV type at enrolment.. n¼Number of
subjects who have at least one follow-up visit after Day 1.
Table 7 Clinical adverse experience summary (entire study duration)
Vaccine
(N¼1908)
n (%)
Placebo
(N¼1902)
n (%)
Subjects in analysis population 1908 1902
Subjects with follow-up 1890 1888
Number (%) of subjects
With one or more adverse experiences 1645 (87.0) 1535 (81.3)
Injection-site adverse experiences 1450 (76.7) 1213 (64.2)
Systemic adverse experiences 1121 (59.3) 1135 (60.1)
With vaccine-related adverse experiences 1565 (82.8) 1391 (73.7)
Injection-site adverse experiences 1449 (76.7) 1213 (64.2)
Systemic adverse experiences 746 (39.5) 697 (36.9)
With serious adverse experiences 14 (0.7) 16 (0.8)
With serious vaccine-related adverse
experiences
0 (0.0) 0 (0.0)
Discontinued due to an adverse
experience
7 (0.4) 2 (0.1)
discontinued due to a vaccine-related
adverse experience
a
5 (0.3) 2 (0.1)
Discontinued due to a serious adverse
experience
2 (0.1) 0 (0.0)
Discontinued due to a serious
vaccine-related adverse experience
0 (0.0) 0 (0.0)
Who died
b 7 (0.4) 1 (0.1)
N¼number of subjects receiving at least one dose of vaccine or placebo with non-
missing safety data; n¼number of subjects contributing to the analysis.
aReasons for
discontinuation due to a vaccine-related adverse experience in the vaccine group
included hypersensitivity, urticaria, mouth ulceration, injection-site swelling, and facial
oedema. Reasons for discontinuation due to a vaccine-related adverse experience in
the placebo group included fatigue and overdose.
bReasons for death in the
vaccine group included cardiac arrest secondary to breast cancer metastasis, cardiac
arrest secondary to cerebrovascular accident, acute liver disease secondary to
nasopharyngeal cancer, breast cancer, tuberculosis, pulmonary embolism, and
pericarditis. Reasons for death in the placebo group included pulmonary embolism.
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previous results on the immunogenicity, safety, and high efficacy
of the qHPV vaccine in adult women up to 45 years of age,
regardless of previous exposure to HPV vaccine types.
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